The aim of this study is to investigate tumor response, safety and immune response induction in patients with advanced BCC treated with a combination of anti-PD1 antibody and pulsed hedgehog inhibitor.
Aim of the study
We are investigating advanced basal cell carcinoma. This study will provide new insights into the efficacy, safety and tolerability of the combination therapy of an anti-PD1 antibody (cemiplimab) and a hedgehog inhibitor (sonidegib, also known as HHI for short).
Who can take part?
Patients with advanced BCC
Procedure
The study consists of 4 parts: a pre-examination part, a treatment part, the end of treatment and a follow-up part. The following measures are required for this study: blood samples, tumor biopsies, imaging examinations, tumor measurements, photographs and telephone contact with women of childbearing age.
Compensation
None
Original study name
A prospective, open-label, single-arm phase II study to evaluate the efficacy of an anti-PD1 antibody in combination with a pulsed hedgehog inhibitor in advanced basal cell carcinoma
BASEC number
2020-01935
Financial support from
University of Zurich